BioNTech's ADC Trastuzumab Pamirtecan Delivers Strong Phase 2 Efficacy in Endometrial Cancer
BNTX sits 20% above its 52-week low of $79.52.
Summary
BioNTech announced positive primary analysis results from a Phase 2 cohort for its antibody-drug conjugate (ADC) trastuzumab pamirtecan (BNT323/DB-1303) in patients with HER2-expressing, recurrent endometrial cancer. The drug demonstrated clinically meaningful efficacy and a manageable safety profile, with an objective response rate (ORR) of 49.3% in a key subgroup and 47.9% in all centrally tested patients, alongside a median progression-free survival (mPFS) of 8.1 months. This news is a significant update on BioNTech's pipeline, with no prior timeline entries related to this specific drug's clinical trial results, making this fresh information. These strong Phase 2 results de-risk a key pipeline asset for BioNTech, particularly in an area with high unmet medical need and increasing mortality rates. The efficacy across all HER2 expression levels is particularly encouraging, broadening the potential patient population and supporting the ongoing global confirmatory Phase 3 clinical trial. Investors will now closely monitor the progress of the Phase 3 trial and any further regulatory updates.
At the time of this announcement, BNTX was trading at $95.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24B. The 52-week trading range was $79.52 to $124.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.